amina tarek mneimneh - repository.bau.edu.lb:8080
TRANSCRIPT
Design and Development of Biocompatible Lipid-based Nanocarriers
By
Amina Tarek Mneimneh
Thesis
Presented to fulfill the requirements of Master degree in Pharmaceutical
Sciences
(Pharmaceutics and Pharmaceutical Technology)
Department of Pharmaceutical Technology
Faculty of Pharmacy
2019
Design and Development of Biocompatible Lipid-based Nanocarriers.
By
Amina Tarek Mneimneh
Thesis
Presented to fulfill the requirements of Master degree in Pharmaceutical
Sciences
(Pharmaceutics and Pharmaceutical Technology)
Department of Pharmaceutical Technology
Faculty of Pharmacy
Supervised by
Dr. Mohammed M. Mehanna
Assistant Prof. of Pharmaceutical Technology
Faculty of Pharmacy
Beirut Arab University
2019
i
Abstract
Synthesis of new drug alone has been evident to be insufficient to establish
advancement in drug therapy. The conventional drug delivery systems are destined to failure,
due to many factors, mainly low drug solubility, absorption, enzymatic hydrolysis, rapid
metabolism, cellular efflux and variability in plasma concentration. Lipid-based nanocarriers
provide a great prospective of overcoming various technological and stability limitations of
the conventional delivery systems. Lipids can offer wide range of diverse nanocarriers
including, liposomes, niosomes, solid-lipid nanoparticles, lipid-drug conjugate,
nanostructured lipid carriers, microemulsion, nanoemulsion and self-emulsifying delivery
system. Our aim in the current study was to develop and optimize a spontaneous self-
nanoemulsifying drug delivery system (SNEDDS), containing D-limonene as the oily phase,
and Tween®80/propylene glycol mixture as surfactant/co-surfactant. The work was
distributed on three chapters; preparation and optimization of limonene-based self-
nanoemulsifying delivery system, in-vivo evaluation of the tadalafil-loaded SNEDS for its
gastroprotective effect, and in-vitro assessment of levofloxacin-loaded SNEDS for its
antimicrobial activity against Methicillin-resistant Staphylococcus aureus (MRSA)
producing biofilms, and its formulation as an ocular in-situ nanoemulgel.
The optimization of the SNEDS was achieved through the construction of a pseudo-
ternary phase diagram. Limonene-based SNEDS was optimized by evaluating its
physiochemical properties, namely; droplet size, zeta potential, polydispersity index and its
morphology was studied by transmittance electron microscopy. In addition, the stability in
different storage conditions of the formulation for three months was assessed. The optimized
limonene-based SNEDS had the smallest droplet size (113.3 nm), unimodel distribution with
PDI (0.211), the highest percentage transmittance (92.57%) and optimal zeta potential of -
19.13 mV and was stable during the period of study.
Furthermore, the optimized SNEDS was loaded with tadalafil then tested in-vivo for
its protective effect against ethanol-induced injuries in rats, compared to omeprazole. The
results showed significant high gastroprotection percentage (99.59%) in the limonene-based
SNEDS and tadalafil-loaded preparation (99.9%) compared to the omeprazole pre-treated
group (74%). The histological analysis displayed very mild inflammation in the limonene-
ii
based nanoemulsion group with an intact mucosal structure while normal intact epithelial
layer was noticed in tadalafil-loaded SNEDS pretreated group.
Levofloxacin-loaded limonene-based SNEDS was evaluated in-vitro for its
antimicrobial susceptibility on biofilm forming MRSA strain through kinetics of killing and
biofilm assay. The in-situ nanoemulgel ocular irritation was studied by HET-CAM test. The
results revealed that levofloxacin-loaded limonene-based SNEDS showed improved efficacy
to eradicate MRSA biofilm, where the MIC of the loaded SNEDS was 3.12 mg/ml less than
that of drug alone 6.25 mg/ml. HET-CAM test showed no signs of hemorrhage, coagulation
or lysis for the loaded nanoemulgel same as the negative control. The irritation score was
zero. The data and knowledge accumulated from this research suggested that self-
nanoemulsifying delivery system loaded gel is a promising alternative to standard antibiotic
dosage forms against antibiotic-resistant bacteria and those which form impassable biofilms.
iii
Table of Contents List of tables vii
List of figures ix
List of Abbreviation xii
Introduction 1
1. Lipid formulation classification system 2
2. Type of lipid-based drug delivery system 3
2.1. Vesicular systems 3
2.2. Lipid particulate systems 9
2.3. Emulsions 13
Chapter Ⅰ 1
Self-Nanoemulsifying Drug Delivery System Based on D-limonene: Design and Optimization 1
1. Introduction 25
Aim of the chapter 28
2. Materials and methods 29
2.1. Materials 29
2.2. Preliminary screening of surfactants 29
2.3. Preliminary screening of co-surfactants 29
2.4. Construction of pseudoternary phase diagram 29
2.5. Preparation of limonene-based self-nanoemulsifying delivery system 30
2.6. Study of SNEDS characteristics 30
2.6.1. Macroscopic examination 30
2.6.2. Turbidity/transparency measurement 30
2.6.3. Self-emulsification time determination 30
2.6.4. Cloud point determination 31
2.6.5. Transmission electron microscopy (TEM) 31
2.6.6. Globule size and zeta potential measurements 31
2.7. Evaluation of the self-nanoemulsifying delivery system 31
2.7.1 Robustness to dilution 31
2.7.1. Thermodynamic stability studies 32
2.8. Stability upon storage 32
2.9. Statistical analysis 32
iv
3. Results 33
3.1. Selection of surfactants and co-surfactants 33
3.2. Pseudoternary phase diagram of limonene-based SNEDS 34
3.3. Physiochemical characteristics and evaluation of limonene-based SNEDS 37
3.4. Storage stability testing 39
4. Discussion 42
5. Conclusion 46
Chapter II 25
Appraisal of Tadalafil-loaded Limonene-based Self-nanoemulsifying Delivery System Gastroprotective Effect Employing Ethanol-induced Mucosal Injuries Model in Rats 25
1. Introduction 47
Aim of the chapter 50
2. Materials and methods 51
2.1. Materials 51
2.2. UV-VIS Spectrophotometric Assay of Tadalafil 51
2.3. Solubility studies 51
2.4. Formulation of tadalafil-loaded limonene-based SNEDS 51
2.5. Evaluation of tadalafil-loaded limonene-based SNEDS 52
2.5.1. Percentage transmittance measurement 52
2.5.2. Self-emulsification time 52
2.5.3. Robustness to dilution 52
2.5.4. Cloud point determination 52
2.5.5. Thermodynamic stability 52
2.6. Physiochemical characteristics of tadalafil-loaded limonene-based SNEDS 53
2.6.1. Determination of droplet size and polydispersity index (PDI) 53
2.6.2. Zeta potential measurement 53
2.6.3. In-vitro drug release and its kinetics 53
2.7. In-vivo assessment 55
2.7.1. Animals 55
2.7.2. Ethanol-induced gastric ulcer 55
2.7.3. Evaluation of gastric lesion 55
2.7.4. Histopathological assessment 56
v
2.8. Stability studies 56
2.9. Statistical analysis 57
3. Results 58
3.1. UV-VIS spectrophotometric Assay of Tadalafil 58
3.2. Solubility study 59
3.3. Physical stability of tadalafil SNEDS 59
3.4. Physicochemical characteristics of tadalafil-loaded nanoemulsion 60
3.5. In-vitro dissolution studies 60
3.6. Gross evaluation 62
3.7. Histopathological evaluation 66
3.8. Storage stability 66
4. Discussion 70
5. Conclusion 75
Chapter III 47
Levofloxacin-loaded Naturally Occurring Monoterpine-based Nanoemulgel: A Feasible Efficient System to Circumvent MRSA Ocular Infections 47
1. Introduction 76
Aim of the chapter 79
2. Materials and methods 80
2.1. Materials and culture 80
2.2. UV-VIS Spectrophotometric Assay of levofloxacin 80
2.3. Solubility study 80
2.4. Preparation of levofloxacin-loaded limonene-based SNEDS 80
2.5. Assessment of levofloxacin-loaded limonene-based SNEDS 81
2.5.1. Thermodynamic stability 81
2.5.2. Self-emulsification time 81
2.5.3. Robustness to dilution 81
2.5.4. Cloud point 81
2.6. Physiochemical characteristics of the levofloxacin-loaded SNEDS 81
2.7. Antibacterial activity of levofloxacin-loaded and unloaded SNEDS 82
2.7.1. Determination of the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) 82
vi
2.7.2. Effect of limonene-based SNEDS on the activity of levofloxacin against biofilm-forming bacteria 82
2.7.3. Regrowth assay 83
2.8. Storage stability 83
2.9. Preparation of levofloxacin-loaded limonene-based in-situ nanoemulgel 83
2.10. Characterization of the levofloxacin-loaded limonene-based in-situ nanoemulgel 84
2.10.1. Determination of visual appearance, clarity and pH 84
2.10.2. Measurement of the gelation temperature 84
2.10.3. Rheological behavior 84
2.10.4. Refractive index 84
2.10.5. Transmission electron microscopy (TEM) 84
2.11. In-vitro release of levofloxacin from limonene-based in-situ nanoemulgel 85
2.12. Ocular irritation test by Hen's Egg Test Chorioallantoic Membrane (HET-CAM) Assay 85
2.13. Statistical analysis 86
3. Results 87
3.1. UV-VIS spectrophotometric Assay of Levofloxacin 87
3.2. Solubility study 88
3.3. Physiochemical characteristics and physical stability of Levofloxacin- loaded limonene-based SNEDS 88
3.4 . Antibacterial activity of levofloxacin-loaded and unloaded limonene-based SNEDS 91
3.4.1. In-vitro evaluation of the activity of levofloxacin-loaded and free limonene-based SNEDS 91
3.4.2. Effect of levofloxacin loaded and unloaded limonene-based SNEDS on the biofilm-forming ability of MRSA 91
3.4.3. Biofilm regrowth assay 93
3.5. Storage stability 94
3.6. Characterization of the levofloxacin-loaded limonene-based in-situ nanoemulgel 95
3.7. In-vitro release studies 97
3.8. Hen's Egg Test Chorioallantoic Membrane (HET-CAM) irritation test 98
4. Discussion 101
5. Conclusion 106
References 107
vii
List of tables Table 1: Lipid formulation classification system; characteristic features, advantages, and
disadvantages of the basic lipid formulations7 2
Table 2: Differences between nanoemulsions and microemulsions58,59 14
Table 3: Summary of some research articles describing different SNEDDS formulations 22
Table 4: Preliminary screening of different surfactants and co-surfactants based on their %
transmittance 33
Table 5: Analysis of variance of surfactants and co-surfactants screening 34
Table 6: Composition of SNEDS formulations constructing phase diagram 35
Table 7: Physiochemical characteristics of limonene-based SNEDS* 37
Table 8: Abou Zeit-Har ulcer scoring system 56
Table 9: Thermodynamic stability and self-emulsification time tadalafil-loaded and unloaded
limonene-based self-nanoemulsifying delivery system 59
Table 10: T-test values of the physiochemical characteristics of tadalafil-loaded and unloaded
limonene-based nanoemulsion 60
Table 11: T-test values of the mean dissolution rate of tadalafil from limonene-based SNEDS
and aqueous suspension 61
Table 12: Correlation coefficients and kinetics of drug release of tadalafil from limonene-
based self-emulsifying delivery system 62
Table 13: The effect of different treatment modalities on ethanol-induced gastric ulcer in
rats● 65
Table 14: Physical stability of tadalafil-loaded SNEDS at different storage temperatures for
three months* 68
Table 15: Scoring scheme for the Hen's Egg Test-chorioallantoic membrane test for
membrane irritation 86
Table 16: Physiochemical characteristics of Levofloxacin-loaded limonene based SNEDS 89
Table 17: T-test of the physiochemical characteristics of levofloxacin-loaded and unloaded
SNEDS 89
Table 18: MIC and MBC values of levofloxacin aqueous solution, levofloxacin-loaded and
unloaded limonene-based self-nanoemulsifying delivery system against 49 MRSA strain* 92
Table 19: T-test value for biofilm inhibition of free and loaded levofloxacin SNEDS 93
1
In the recent years, it has been evident that synthesizing new drug alone is not
sufficient to establish advancement in drug therapy. The conventional drug delivery
systems are destined to failure, due to many factors, mainly low drug solubility, poor
absorption, enzymatic degradation, rapid metabolism, cellular efflux and variability in
plasma concentration1. Poorly soluble drugs are a considerable challenge for researchers,
regarding their low aqueous solubility, bioavailability and high lipophilicity. So, a new
pharmaceutical delivery system or a drug carrier that acts as a reservoir is needed for the
optimal delivery of drug to the targeted site within appropriate time frame and effective
concentration. In-vivo fate of the drug isn’t influenced only by the properties of the drug
itself, but also by its carrier system characteristics, which could provide controlled or
localized release of the drug according to the desired therapy2. Lipids are the major
constituents of biological membranes. Incorporation of lipids in drug delivery has been a
trend in the past decades. Lipid based carriers are composed of phospholipids, cholesterol,
cholesterolesters and triglycerides among others3. The physiochemical diversity of lipids,
their biocompatibility and their resemblance to body tissue constituents offer a promising
system for poorly water soluble and lipophilic drugs4. Lipid carriers (LCs) provide several
advantages that enable it to be an ideal vehicle for drug delivery. Namely; it can be
manipulated according to product requirements whether its disease conditions, rout of
administration, stability, toxicity or efficacy. In addition, Lipid based formulations (LBFs)
can provide a controlled release delivery based on their biocompatibility with body tissue
after administration, it’s not susceptible to erosion phenomena, feasibility of scaling up5,
moreover, it provide enhanced drug loading, ability to carry both lipophilic and
hydrophilic drugs and stability. However, LCs face certain limitations such as, lipid
crystallization that leads to polymorphism with different drug loading capacity, different
shapes and various kinetic distributions. High pressure homogenization technique is most
commonly used and it might cause drug degradation in high molecular weight
compounds3. Lipid-based carriers are recognized as safe and efficient hence they have
been used as alluring candidates for pharmaceutical, as well as vaccines, diagnostics, and
nutraceutical formulations. Therefore, lipid-based drug delivery (LBDD) systems have
gained much importance in the recent years due to their ability to improve the solubility
and bioavailability of drugs with poor water solubility.
107
1. Zaro, J. L. (2015). Lipid-Based carriers for prodrugs to enhance delivery. 17, 83–
92
2. Mehnert, W. & Mäder, K. (2001). Solid lipid nanoparticles production,
characterization and applications. Adv. Drug Deliv. Rev. 47, 165–196
3. Rawat, M., Singh, D., Saraf, S. & Swarnlata, S. (2008). Lipid carriers: A versatile
delivery vehicle for proteins and peptides. Pharm. Soc. Japan 128, 269–280
4. Colin W.Pouton. (2006). Formulation of poorly water-soluble drugs for oral
administration: physicochemical and physiological issues and the lipid formulation
classification system. Eur. J. Pharm. Sci. 29, 278–287
5. Reithmeier, H., Herrmann, J. & Göpferich, A. (2001). Development and
characterization of lipid microparticles as a drug carrier for somatostatin. Int. J.
Pharm. 218, 133–143
6. Mehanna, M., Motawaa, A. & Samaha, M. (2012). Pharmaceutical particulate
carriers: lipid - based carriers. Natl. J. Physiol. Pharm. Pharmacol. 2, 10–22
7. Shrestha, H., Bala, R. & Arora, S. (2014). Lipid-based drug delivery systems. J.
Pharm. 2014, 1–10
8. Mishra, D. K., Ruchita, S. & Pradyumna, K. M. (2018). Lipid based nanocarriers: a
translational perspective. Nanomedicine Nanotechnology, Biol. Med. 14, 2023–
2050
9. Deshpande, P., Aditi, J., Bhushan, P., Biswas, S. & Torchilin, V. (2018).
Transferrin and octaarginine modified dual functional liposomes with improved
cancer cell targeting and enhanced intracellular delivery for the treatment of
ovarian cancer. Drug Deliv. 25, 517–532
10. Meng, J. et al. (2016). Combination therapy using co-encapsulated resveratrol and
paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo.
Sci. Rep. 1–11
11. Wetzler, M. et al. (2014). Phase I/II trial of nanomolecular liposomal annamycin in
adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin.
Lymphoma, Myeloma Leuk. 13, 430–434
12. Bulbake, U., Doppalapudi, S., Kommineni, N. & Khan, W. (2017). Liposomal
formulations in clinical use : an updated review development. Pharmaceutics 9, 1–
33
108
13. Food and Drug Adminstration. (2018). FDA approves a new antibacterial drug to
treat a serious lung disease using a novel pathway to spur innovation. Available at:
www.fda.gov.
14. Jyoti, K., Pandey, R. S., Madan, J. & Jain, U. K. (2016). Inhalable cationic
niosomes of curcumin enhanced drug delivery and apoptosis in lung cancer cells.
Indian J. Pharm. Educ. Res. 50, S23-31
15. Pandita, A. & Sharma, P. (2013). Pharmacosomes: an emerging novel vesicular
drug delivery system for poorly soluble synthetic and herbal drugs. Int. Sch. Res.
Not. Pharm. 2013, 1–10
16. Sailaja, A. K. (2016). Pharmacosomes : a novel carrier for drug delivery.
Innoriginal Int. J. Sci. 3, 1–10
17. Semalty, A., Semalty, M., Rawat, B. S., Singh, D. & Rawat, M. S. M. (2010).
Development and evaluation of pharmacosomes of aceclofenac. Indian J. Pharm.
Sci. 72, 576–581
18. Mirzaei, H. et al. (2017). Phytosomal curcumin: A review of pharmacokinetic,
experimental and clinical studies. Biomed. Pharmacother. 85, 102–112
19. Dubey, V., Mishra, D., Nahar, M. & Jain, N. K. (2007). Vesicles as tools for the
modulation of skin permeability. Expert Opin. Drug Deliv. 4, 579–594
20. Mehanna, M. M., Motawaa, A. M. & Samaha, M. W. (2014). Nanovesicular
carrier-mediated transdermal delivery of tadalafil : i- formulation and
physicochemical characterization. Drug Dev. Ind. Pharm. 41, 714–721
21. Bodade, S. S., Shaikh, K. S., Kamble, M. S. & Chaudhari, P. D. (2013). A study on
ethosomes as mode for transdermal delivery of an antidiabetic drug. Drug Deliv.
20, 40–46
22. Jain, S., Jain, V. & Mahajan, S. C. (2014). Lipid based vesicular drug delivery
systems. Adv. Pharm. 1–12
23. Sutariya, V. & Patel, P. (2012). Aquasomes: a novel carrier for drug delivery. Int.
J. Pharm. Sci. Res. 3, 688–694
24. Alavi, M., Karimi, N. & Safaei, M. (2017). Application of various types of
liposomes in drug delivery systems. Adv. Pharm. Bull. 7, 1–9
25. Abd-Elal, R. M. A., Shamma, R. N., Rashed, H. M. & Bendas, E. R. (2016). Trans-
nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo
evaluation of brain targeting efficiency. Drug Deliv. 23, 3374–3386
26. Thompson, K. L., Williams, M. & Armes, S. P. (2014). Colloidosomes : Synthesis ,
109
properties and applications. J. Colloid Interface Sci. 447, 217–228
27. Shah, R. K., Kim, J. & Weitz, D. A. (2010). Monodisperse stimuli-responsive
colloidosomes by self-assembly of microgels in droplets. Langmuir 26, 1561–1565
28. Nan, F. et al. (2014). Preparation of uniform-sized colloidosomes based on
chitosan-coated alginate particles and its application for oral insulin delivery. J.
Mater. Chem. B Mater. Biol. Med. 00, 1–7
29. Ghasemiyeh, P. & Mohammadi-Samani, S. (2018). Solid lipid nanoparticles and
nanostructured lipid carriers as novel drug delivery systems: applications,
advantages and disadvantages. Res. Pharm. Sci. 13, 288–303
30. Gasco, M. R. (2007). Lipid nanoparticles: perspectives and challenges. Adv. Drug
Deliv. Rev. 59, 377–378
31. Yuan, H. et al. (2007). Studies on oral absorption of stearic acid SLN by a novel
fluorometric method. Colloids Surfaces B Biointerfaces 58, 157–164
32. Pardeike, J., Hommoss, A. & Müller, R. . (2009). Lipid nanoparticles (SLN, NLC)
in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 366, 170–184
33. Bunjes, H. (2010). Lipid nanoparticles for the delivery of poorly water-soluble
drugs. J. Pharm. Pharmacol. 62, 1637–1645
34. Anthony, A. A., Stephan, R. & Müller-Goymann, C. . (2008). Diclofenac sodium
delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation
using human cornea construct. Int. J. Pharm. 355, 307–313
35. Chime, S. & Onyishi, I. (2013). Lipid based drug delivery systems (LDDS): recent
advances and applications of lipids in drug delivery. African J. Pharm. Pharmacol.
7, 3034–3059
36. Dudala, T. B. et al. (2014). A perspective overview on lipospheres as lipid carrier
systems. Int. J. Pharmceutical Investig. 4, 149–155
37. Nasr, M., Mansour, S., Mortada, N. D. & El Shamy, A. A. (2008). Lipospheres as
carriers for topical delivery of Aceclofenac : preparation , characterization and in
vivo evaluation. AAPS PharmSciTech 9, 154–162
38. Patidar, A., Kumar, P., Verma, J. & Thakur, D. (2010). A review on novel lipid
based nanocarriers. Int. J. Pharm. Pharm. Sci. 2, 30–35
39. Mühlen, A. zur, Schwarz, C. & Wolfgang, M. (1998). Solid lipid nanoparticles
(SLN) for controlled drug delivery – drug release and release mechanism. Eur. J.
Pharm. Biopharm. 45, 149–155
40. Naseri, N., Valizadeh, H. & Zakeri-Milani, P. (2015). Solid lipid nanoparticles and
110
nanostructured lipid carriers: structure, preparation and application. Adv. Pharm.
Bull. 5, 305–313
41. Kelidari, H. R. et al. (2018). Improved delivery of voriconazole to Aspergillus
fumigatus through solid lipid nanoparticles as an effective carrier. Colloids
Surfaces A Physicochem. Eng. Asp. 558, 338–342
42. Dara, T. et al. (2019). Erythropoietin-loaded solid lipid nanoparticles: preparation,
optimization, and in vivo evaluation. Colloids Surfaces B Biointerfaces 178, 307–
316
43. Müller, R., Wissing, S. & Radtke, M. (2002). Nanostructured lipid matrices for
improved microencapsulation of drugs. Int. J. Pharm. 242, 121–128
44. Beloqui, A. et al. (2014). Biodistribution of nanostructured lipid carriers (NLCs)
after intravenous administration to rats: influence of technological factors. Eur. J.
Pharm. Biopharm. 84, 309–314
45. Shen, J. et al. (2010). Thiolated nanostructured lipid carriers as a potential ocular
drug delivery system for cyclosporine A: Improving in vivo ocular distribution. Int.
J. Pharm. 402, 248–253
46. Khuranaa, S., Jain, N. . & Bedi, P. M. . (2013). Development and characterization
of a novel controlled release drug delivery system based on nanostructured lipid
carriers gel for meloxicam. Life Sci. 93, 763–772
47. Fathi, H. A., Allam, A., Elsabahy, M., Fetih, G. & El-Badry, M. (2018).
Nanostructured lipid carriers for improved oral delivery and prolonged
antihyperlipidemic effect of simvastatin. Colloids Surfaces B Biointerfaces 162,
236–245
48. Salvi, V. R. & Pawar, P. (2019). Nanostructured lipid carriers ( NLC ) system : A
novel drug targeting carrier. J. Drug Deliv. Sci. Technol. 51, 255–267
49. Beloqui, A., Solinís, M. Á., Rodríguez-gascón, A., Almeida, A. J. & Préat, V.
(2016). Nanostructured lipid carriers : Promising drug delivery systems for future
clinics. Nanomedicine Nanotechnology, Biol. Med. 12, 143–161
50. Irby, D., Du, C. & Li, F. (2017). Lipid − drug conjugate for enhancing drug
delivery. Mol. Pharm. 14, 1325–1338
51. Bradley, M. O. et al. (2001). Tumor targeting by covalent conjugation of a natural
fatty acid to paclitaxel. Clin. Cancer Res. 7, 3229–3238
52. LU, G. W. & Gao, P. (2010). Emulsions and microemulsions for topical and
transdermal rug delivery. in Handbook of Non-Invasive Drug Delivery Systems 59–
111
94
53. Hoar, T. P. & Schulman, J. H. (1943). Transparent water-in-oil dispersions: the
oleopathic hydro-micelle. Nat. Int. J. Sci. 152, 102–103
54. Patil, N. H. & Devarajan, P. V. (2014). Colloidal carriers for noninvasive delivery
of insulin. in Colloid and Interface Science in Pharmaceutical Research and
Development 411–442
55. Patel, H., Parejiya, P., Shelat, P., Shukla, A. & Barot, B. S. (2013). Topical
delivery of clobetasol propionate loaded microemulsion based gel for effective
treatment of vitiligo: Ex vivo permeation and skin irritation studies. Colloids
Surfaces B Biointerfaces 102, 86–94
56. Shah, B. R. et al. (2016). Preparation and optimization of pickering emulsion
stabilized by chitosan-tripolyphosphate nanoparticles for curcumin encapsulation.
Food Hydrocoll. 52, 369–377
57. McClements, D. J. (2011). Edible nanoemulsions: fabrication, properties, and
functional performance. Soft Matter 2297–2316
58. Mcclements, D. J. (2012). Nanoemulsions versus microemulsions : terminology ,
differences , and similarities. Soft Matter 8, 1719–1729
59. Anton, N. & Vandamme, T. (2011). Nano-emulsions and Micro-emulsions:
Clarifications of the Critical Differences. Pharm. Res. 28, 978–985
60. Shafiq, S. et al. (2007). Development and bioavailability assessment of ramipril
nanoemulsion formulation. Eur. J. Pharm. Biopharm. 66, 227–243
61. Bali, V., Ali, M. & Ali, J. (2010). Study of surfactant combinations and
development of a novel nanoemulsion for minimizing variations in bioavailability
of ezetimibe. Colloids surfaces B Biointerfaces 76, 410–420
62. Wang, X. et al. (2008). Enhancing antiinflammation activity of curcumin through
O/W nanoemulsions. Food Chem. 108, 419–424
63. Patravale, V. B. & Mandawgade, S. D. (2008). Novel cosmetic delivery systems :
an application update. Int. J. Cosmet. Sci. 30, 19–33
64. Jasmina, H., Džana, O., Alisa, E., Edina, V. & Ognjenka, R. (2017). Preparation Of
nanoemulsions by high-energy and low energy emulsification methods. IFMBE
Proc. 62, 316–322
65. Kumari, C. T. L., Sowjanya, G. N., S.L.Sindhuri & P.Bandhavi. (2012).
Nanoemulsions an emerging trend: a review. Int. J. Pharm. Res. Dev. 4, 137–152
66. Gonçalves, A. et al. (2018). Production, properties, and applications of solid self-
112
emulsifying delivery systems (S-SEDS) in the food and pharmaceutical industries.
Colloids Surfaces APhysicochemical Eng. Asp. 538, 108–126
67. Maali, A. & Mosavian, M. T. H. (2013). Preparation and application of
nanoemulsions in the last decade (2000–2010). J. Dispers. Sci. Technol. 34, 92–
105
68. Shinoda, K. & Saito, H. (1968). The effect of temperature on the phase equilibria
and the types of dispersions of the ternary system composed of water, cyclohexane,
and nonionic surfactant. J. Colloid Interface Sci. 26, 70–74
69. Anton, N. et al. (2009). Aqueous-core lipid nanocapsules for encapsulating fragile
hydrophilic and/or lipophilic molecules. Langmuir 25, 11413–11419
70. Fernandes, C. et al. (2012). Investigation of the mechanisms underlying the
gastroprotective effect of cymbopogon citratus essential oil. J. Young Pharm. 4,
28–32
71. Maestro, A., Solè, I., González, C., Solans, C. & Gutiérrez, J. M. (2008). Influence
of the phase behavior on the properties of ionic nanoemulsions prepared by the
phase inversion composition method. Colloid Interface Sci. Pharm. Res. Dev. 327,
433–439
72. Shakeel, F., Baboota, S., Ahuja, A., Ali, J. & Shafiq, S. (2009). Celecoxib
nanoemulsion for transdermal drug delivery: characterization and invitro
evaluation. J. Dispers. Sci. Technol. 30, 834–842
73. Bouchemal, K., Briançon, S., Perrier, E. & Fessi, H. (2004). Nano-emulsion
formulation using spontaneous emulsification: solvent, oil and surfactant
optimisation. Int. J. Pharm. 280, 241–251
74. Mahajan, H. S., Mahajan, M. S., Nerkar, P. P. & Agrawal, A. (2014).
Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for
brain targeting. Drug Deliv. 21, 148–154
75. Oliveira, C. A. et al. (2018). Nanoemulsion containing 8-methoxypsoralen for
topical treatment of dermatoses : Development , characterization and ex vivo
permeation in porcine skin. Int. J. Pharm. 547, 1–9
76. Chauhan, S. & Batra, S. (2018). Development and in-vitro characterization of
nanoemulsion embedded thermosensitive in-situ ocular gel of diclofenac sodium
for sustained delivery. Int. J. Pharm. Sci. Res. 9, 2301–2314
77. Li, Y., Hu, X., Lu, X., Liao, D. & Tang, T. (2017). Nanoemulsion-based delivery
system for enhanced oral bioavailability and Caco-2 cell monolayers permeability
113
of berberine hydrochloride. Drug Deliv. 24, 1868–1873
78. Thakur, N., Garg, G., Sharma, P. K. & Kumar, N. (2012). Nanoemulsions : a
review on various pharmaceutical application. Glob. J. Pharmacol. 6, 222–225
79. Fofaria, N. M., Syed, H., Qhattal, S., Liu, X. & Srivastava, S. K. (2017).
Nanoemulsion formulations for anti-cancer agent piplartine – characterization,
toxicological, pharmacokinetics and efficacy studies. Int. J. Pharm. 498, 12–22
80. Ribeiro, R. C. de A. et al. (2015). Production and characterization of cosmetic
nanoemulsions containing Opuntia ficus-indica (L.) mill extract as moisturizing
agent. Molecules 20, 2492–2509
81. Gursoy, R. & Benita, S. (2004). Self-emulsifying drug delivery systems (SEDDS)
for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58, 173–
182
82. Singh, B., Kapil, R., Singh, R., Katare, O. & Bandopadhyay, S. (2009). Self-
emulsifying drug delivery systems (SEDDS): formulation development,
characterization, and applications. Crit. Rev. Ther. Drug Carr. Syst. 26, 427-521
83. Khan, A., Ansari, S., Sharma, R., Ali, J. & Kotta, S. (2012). Potentials and
challenges in self-nanoemulsifying drug delivery systems. Expert Opin. 10, 1305–
1317
84. Chime, S. A., Kenechukwu, F. C. & Attama, A. A.(2013) Nanoemulsions —
advances in formulation,characterization and applications in drug delivery. in
Application of Nanotechnology in Drug Delivery, 77–126
85. Kohli, K., Chopra, S., Dhar, D., Arora, S. & Roop, K. K. (2010). Self-emulsifying
drug delivery systems: an approach to enhance oral bioavailability. Drug Discov.
Today 15, 958–968
86. Thomas, N., Graf, A., Rades, T. & Müllertz, A. (2012). Influence of lipid
composition and drug load on the in vitro performance of self-nanoemulsifying
drug delivery systems. J. Pharm. Sci. 101, 1721–1731
87. Shah, N. H., Patel, C. I., Nfeld, M. H., Malick, A. W. & Carvajal, M. (1994). Self-
emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for
improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J.
Pharm. 106, 15–23
88. Date, A. A., Desai, N. & Nagarsenker, M. (2010). Self-nanoemulsifying drug
delivery systems : formulation insights , applications and advances. Nanomedicine
5, 1595–1616
114
89. Fahmy, U., Hosny, K. & Ahmed, O. (2014). Development and evaluation of
avanafil self-nanoemulsifying drug delivery system with rapid onset of action and
enhanced bioavailability. Am. Assoc. Pharm. Sci. 16, 53–58
90. Reiss, H. (1975). Entropy-induced dispersion of bulk liquids. J. Colloid Interface
Sci. 53, 61–70
91. Groves, M. & Galindez, D. de. (1976). The self-emulsifying action of mixed
surfactants in oil. Acta Pharm. Suec. 13, 361–372
92. Rehman, F. U., Shah, K. U., Shah, S. U. & Khan, I. U. (2016). From
nanoemulsions to self-nanoemulsions , with recent advances in self-
nanoemulsifying drug delivery systems ( SNEDDS ). Expert Opin. Drug Deliv.
5247, 1–16
93. Abd-Elhakeem, E., Teaima, M. H., Abdelbary, G. A. & El Mahrouk, G. M. (2019).
Bioavailability enhanced clopidogrel -loaded solid SNEDDS: development and in-
vitro/in-vivo characterization. J. Drug Deliv. Sci. Technol. 49, 603–614
94. Joshi, R. et al. (2013). SNEDDS curcumin formulation leads to enhanced
protection from pain and functional deficits associated with diabetic neuropathy:
An insight into its mechanism for neuroprotection. Nanomedicine Nanotechnology,
Biol. Med. 9, 776–785
95. Abo Enin, H. A. & Abdel-bar, H. M. (2016). Solid super saturated self-
nanoemulsifying drug delivery system ( sat-SNEDDS ) as a promising alternative
to conventional SNEDDS for improvement rosuvastatin calcium oral
bioavailability. Expert Opin. Drug Deliv. 5247, 1–29
96. Dash, R. N., Habibuddin, M., Humair, T. & Ramesh, D. (2015). Design,
optimization and evaluation of glipizide solid self-nanoemulsifying drug delivery
for enhanced solubility and dissolution. Saudi Pharm. J. 23, 528–540
97. Shakeel, F., Haq, N., El-badry, M., Alanazi, F. K. & Alsarra, I. A. (2013). Ultra
fine super self-nanoemulsifying drug delivery system ( SNEDDS ) enhanced
solubility and dissolution of indomethacin. J. Mol. Liq. 180, 89–94
98. Zhang, X. et al. (2013). Controlled release of cyclosporine a self-nanoemulsifying
systems from osmotic pump tablets: near zero-order release and pharmacokinetics
in dogs. Int. J. Pharm. 452, 233–240
99. Miao, Y., Ren, L., Pingkai, O. & Chen, G. (2016). Characterization and evaluation
of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with
enhanced bioavailability and no food effect. Drug Deliv. 23, 2163–2172
115
100. Patil, P. R., Biradar, S. V. & Paradkar, A. R. (2009). Extended release felodipine
self-nanoemulsifying system. Am. Assoc. Pharm. Sci. 10, 515–523
101. Parmar, K., Patel, J. & Sheth, N. (2015). Self nano-emulsifying drug delivery
system for embelin: design, characterization and in-vitro studies. Asian J. Pharm.
Sci. 10, 396–404
102. Mohd, A. B., Sanka, K., Bandi, S. & Diwan, P. V. (2015). Solid self-
nanoemulsifying drug delivery system ( S-SNEDDS ) for oral delivery of
glimepiride : development and antidiabetic activity in albino rabbits. Drug Deliv.
22, 499–508
103. Beg, S., Swain, S., Singh, H. P., Patra, C. N. & Rao, M. B. (2012). Development,
optimization, and characterization of solid self-nanoemulsifying drug delivery
systems of valsartan using porous carriers. Am. Assoc. Pharm. Sci. 13, 1416–1427
104. Dünnhaupt S Waldner C, Kiparissides C, Bernkop-Schnürch A., K. O. (2015).
Nano-carrier systems: strategies to overcome the mucus gel barrier. Eur. J. Pharm.
Biopharm. 96, 447–453
105. Pund, S., Pawar, S., Gangurde, S. & Divate, D. (2015). Transcutaneous delivery of
leflunomide nanoemulgel : mechanistic investigation into physicomechanical
characteristics , in vitro anti-psoriatic and anti-melanoma activity. Int. J. Pharm.
487, 148–156
106. Badran, M. M., Taha, E. I., Tayel, M. M. & Al-Suwayeh, S. A. (2014). Ultra-fine
self nanoemulsifying drug delivery system for transdermal delivery of meloxicam:
Dependency on the type of surfactants. J. Mol. Liq. 190, 16–22
107. Alhakamy, N. A. & Hosny, K. M. (2019). Nano-vesicular delivery system loaded
by bifonazole: Preparation, optimization, and assessment of pharmacokinetic and
antifungal activity. J. Drug Deliv. Sci. Technol. 49, 316–322
108. Hauptstein, S., Bernkop-Schnürch, A. & Prüfert, F. (2015). Self-nanoemulsifying
drug delivery systems as novel approach for pDNA drug delivery. Int. J. Pharm.
487, 25–31
109. Sakloetsakun, D., Dünnhaupt, S., Barthelmes, J., Perera, G. & Bernkop-schnürch,
A. (2013). Combining two technologies : multifunctional polymers and self-
nanoemulsifying drug delivery system ( SNEDDS ) for oral insulin administration.
Int. J. Biol. Macromol. 61, 363–372
110. Garg, V. et al. (2017). Solid self-nanoemulsifying drug delivery systems for oral
delivery of polypeptide-k : formulation , optimization , in-vitro and in-vivo
116
antidiabetic evaluation. Eur. J. Pharm. Sci. 109, 297–315
111. El-Say, K. M., Ahmed, T. A., Ahmed, O. A. A., Hosny, K. M. & Abd-Allah, F. I.
(2017). Self-nanoemulsifying lyophilized tablets (SNELTs) for flash oral
transmucosal delivery of vitamin K: development and clinical evaluation. J.
Pharm. Sci. 106, 2447–2456
112. Pandey, M., Gupta, S., Chikara, S. & Debnath, M. (2011). Phytomedicine: An
ancient approach turning into future potential source of therapeutics. J.
Pharmacogn. Phyther. 3, 113–117
113. Gandhi, G. R. et al. (2019). Essential oils and its bioactive compounds modulating
cytokines: A systematic review on anti-asthmatic and immunomodulatory
properties. Phytomedicine 152854 In,
114. Sienkiewicz, M., Łysakowska, M., Denys, P. & Kowalczyk, E. (2012). The
antimicrobial activity of thyme essential oil against multidrug resistant clinical
bacterial strains. Microb. Drug Resist. 18, 137–148
115. Jongedijk, E. et al. (2016). Biotechnological production of limonene in
microorganisms. Appl. Microbiol. Biotechnol. 100, 2927–2938
116. Li, P.-H. & Lu, W.-C. (2016). Effects of storage conditions on the physical stability
of D-limonene nanoemulsion. Food Hydrocoll. 53, 218–224
117. Paul, E. & Viljoen, A. (2008). Limonene - a review: biosynthetic, ecological and
pharmacological relevance. Nat. Prod. Commun. 3, 1193–1202
118. Lis-Balchin, M., Ochocka, R. J., Deans, S., Asztemborska, M. & Hart, S. (1996).
Bioactivity of the enantiomers of limonene. Med. Sci. Res. 24, 309–310
119. Sun, J. (2007). D-limonene : safety and clinical applications. Altern. Med. Rev. 12,
259–264
120. Vieira, A. J., Beserra, F. P., Souza, M. C., Totti, B. M. & Rozza, A. L. (2018).
Limonene: aroma of innovation in health and disease. Chem. Biol. Interact. 283,
97–106
121. Espina, L., Gelaw, T. K., Lamo-Castellví, S. de, Pagán, R. & García-Gonzalo, D.
(2013). Mechanism of bacterial inactivation by (+)-Limonene and its potential use
in food preservation combined processes. PLoS One 8, 1–10
122. Chee, H. Y., Kim, H. & Lee, M. H. (2009). In vitro antifungal activity of limonene
against Trichophyton rubrum. Mycobiology 37, 243–246
123. Roberto, D., Sebastian, T., Graciela, F., Anesini, C. & Micucci, P. (2009).
Antioxidant activity of Limonene on normal murine lymphocytes: relation to H2O2
117
modulation and cell proliferation. Basic Clin. Pharmacol. Toxicol. 106, 38–44
124. Bacanlı, M., Başaran, N. & Başaran, A. . (2015). The antioxidant and antigenotoxic
properties of citrus phenolics limonene and naringin. Food Chem. Toxicol. 81,
160–170
125. D’Alessio, P. et al. (2013). Oral administration of D-limonene controls
inflammation in rat colitis and displays anti-inflammatory properties as diet
supplementation in humans. Life Sci. 92, 1151–1156
126. Yu, X. et al. (2018). D-limonene exhibits antitumor activity by inducing
autophagy and apoptosis in lung cancer. Onco. Targets. Ther. 11, 1833–1847
127. Zhang, X., Liu, D., Tang, G., Zhang, H. & Wang, L. (2014). Synergistic inhibitory
effect of berberine and D-limonene on human gastric carcinoma cell line
MGC803. J. Med. Food 17, 955–962
128. Ghasemi, S., Assadpour, E., Khomeiri, M. & Mahdi, S. J. (2018).
Nanoencapsulation of D-limonene within nanocarriers produced by pectin-whey
protein complexes. Food Hydrocoll. 77, 152–162
129. Rangsimawong, W., Opanasopit, P., Ngawhirunpat, T., Takayama, K. & Obata, Y.
(2018). Enhancement of galantamine HBr skin permeation using sonophoresis and
limonene-containing PEGylated liposomes. Am. Assoc. Pharm. Sci. 19, 1093–1104
130. Zahi, M., Liang, H., Yuan, Q. & El Hattab, M. (2017). Enhancing the antimicrobial
activity of D-limonene nanoemulsion with the inclusion of ε-polylysine. Food
Chem. 22, 18–23
131. Solans, C. & Solé, I. (2012). Nano-emulsions: formation by low-energy methods.
Curr. Opin. Colloid Interface Sci. 17, 246–254
132. Date, A. A. & Nagarsenker, M. S. (2007). Design and evaluation of self-
nanoemulsifying drug delivery systems(SNEDDS) for cefpodoxime proxetil. Int. J.
Pharm. 329, 166–172
133. Ahmad, J., Amin, S., Kohli, K. & Mir, S. R. (2013). Construction of pseudoternary
phase diagram and its evaluation: development of self-dispersible oral formulation.
Int. J. Drug Dev. Res. 5, 84–90
134. Elnaggar, Y. S. R., El-Massik, M. A. & Abdallah, O. Y. (2009). Self-
nanoemulsifying drug delivery systems of tamoxifen citrate: Design and
optimization. Int. J. Pharm. 380, 133–141
135. Gaikwad, N. M., Shaikh, K. S. & Chaudhari, P. D. (2017). Development and
evaluation of a system for colonic delivery of budesonide. Indian J. Pharm. Educ.
118
Res. 51, 551–561
136. Nasr, A., Gardouh, A. R., Ghonaim, H. M. & Abdelghany, E. (2016). Effect of
oils,surfactants and cosurfactants on phase behavior and physiochemical properties
of self-nanoemulsifying drug delivery system (SNEDDS) for Irbesartan and
Olmesartan. Int. J. Appl. Pharm. 8, 13–24
137. Singh, S., Pathak, K. & Bali, V. (2012). Product development studies on surface-
adsorbed nanoemulsion of olmesartan medoxomil as a capsular dosage form. Am.
Assoc. Pharm. Sci. 13, 1212–1221
138. Yadav, P. S., Yadav, E., Verma, A. & Amin, S. (2014). Development,
characterization, and pharmacodynamic evaluation of hydrochlorothiazide loaded
self-nanoemulsifying drug delivery systems. Sci. World J. 2014, 1–10
139. Drais, H. K. & Hussein, A. A. (2015). Formulation and characterization of
carvedilol nanoemulsion oral liquid dosage form. Int. J. Pharm. Pharm. Sci. 7,
210–216
140. Sureshkumar, R., Bhavani, P. & Gowthamarajan, K. (2015). Nanoemulsion for
lymphatic absorption: investigation of fenofibrate nanoemulsion system for
lymphatic uptake. Int. J. ChemTech Res. 7, 832–841
141. Bernardi, D. S. et al. (2011). Formation and stability of oil-in-water nanoemulsions
containing rice bran oil:in vitro and in vivo assessments. J. Nanobiotechnology 9,
1–9
142. Gupta, A., Eral, H. B., Hattona, T. A. & Doyle, P. S. (2016). Nanoemulsion:
formation,properties and applications. Soft Matter 12, 2826–2841
143. Chouhan, S., Sharma, K. & Guleria, S. (2017). Antimicrobial activity of some
essential oils — present status and future perspectives. MDPI:Medicines 4, 1–21
144. Singh, Y. et al. (2017). Nanoemulsion: concepts,development and applications in
drug delivery. J. Control. Release 252, 28–49
145. Azeem, A. et al. (2009). Nanoemulsion components screening and selection: a
technical note. Am. Assoc. Pharm. Sci. 10, 69–76
146. Pol, A., Hegde, D. & Patel, P. A. (2013). Peppermint oil based drug delivery
system of aceclofenac with improved anti-inflammatory activity and reduced
ulcerogenecity. Int. J. Pharma Biosci. Technol. 1, 89–101
147. Priya, S., Koland, M. & Suchetha, K. N. (2015). Nanoemulsion components
screening of quetiapine fumarate: effect of surfactant and co surfactant. Asian J.
Pharm. Clin. Res. 8, 136–140
119
148. Akhtar, J., Hussain, H. S., Badruddeen, Fareed, S. & Aqil, M. (2014).
Nanomulsion as a carrier for efficient delivery of metformin. Curr. Drug Deliv. 11,
243–252
149. Klang, V., Matsko, N. B., Valenta, C. & Hofer, F. (2012). Electron microscopy of
nanoemulsions: an essential tool for characterisation and stability assessment.
Micron 43, 85–103
150. Ozturka, B., Ozilgen, M., McClements, D. J. & Arginc, S. (2014). Formation and
stabilization of nanoemulsion-based vitamin E delivery systems using natural
surfactants: Quillaja saponin and lecithin. J. Food Eng. 142, 57–63
151. Nekkanti, V., Karatgi, P., Prabhu, R. & Pillai, R. (2010). Solid self-
microemulsifying formulation for candesartan cilexetil. Am. Assoc. Pharm. Sci. 11,
9–17
152. Elsheikh, M. A., Elnaggar, Y. S., Gohar, E. Y. & Abdallah, O. Y. (2012).
Nanoemulsion liquid preconcentrates for raloxifene hydrochloride : optimization
and in vivo appraisal. Int. J. Nanomedicine 7, 3787–3802
153. Gupta, S., Sawant, K. & Chavhan, S. (2011). Self-nanoemulsifying drug delivery
system for adefovir dipivoxil: design, characterization, in vitro and ex vivo
evaluation. Colloids Surfaces A Physicochem. Eng. Asp. 392, 145–155
154. Kallakunta, V. R., Bandari, S., Jukanti, R. & Veerareddy, P. R. (2012). Oral self
emulsifying powder of lercanidipine hydrochloride: formulation and evaluation.
Powder Technol. 221, 375–382
155. Cui, Y., Gu, J., Zhang, T., Zhang, L. & Li, L. (2011). Investigation of
microemulsion system for transdermal delivery of ligustrazine phosphate. African
J. Pharm. Pharmacol. 5, 1674–1681
156. Kazi, M., Al-swairi, M., Ahmad, A. & Raish, M. (2019). Evaluation of self-
nanoemulsifying drug delivery systems ( SNEDDS ) for poorly water-soluble
talinolol : preparation , in vitro and in vivo assessment. Front. Pharmacolgy 10, 1–
13
157. Mahmoud, H., Al-Suwayeh, S. & Elkadi, S. (2013). Design and optimization of
self nanoemulsifying drug delivery systems of simvastatin aiming dissolution
enhancement. African J. Pharm. Pharmacol. 7, 1482–1500
158. Honary, S., Zahir, F. & Honary S, Z. F. (2013). Effect of zeta potential on the
properties of nano-drug delivery systems - A review (Part 1). Trop. J. Pharm. Res.
12, 255–264
120
159. Bayindir, Z. & Yuksel, N. (2010). Characterization of niosomes prepared with
various nonionic surfactants for paclitaxel oral delivery. J. Pharm. Sci. 99, 2049–
2060
160. Dou, Y. et al. (2018). Self-nanoemulsifying drug delivery system of Bruceine D: a
new approach for anti-ulceratice colitis. Int. J. Nanomedicine 13, 5887–5907
161. Henry, J., Frith, W., Norton, I. & Fryer, P. (2010). The influence of phospholipids
and food proteins on the size and stability of model sub-micron emulsions. Food
Hydrocoll. 24, 66–71
162. Eid, A. M. M., ElMarzugi, N. A. & El-Enshasy, H. A. (2013). Preparation and
evaluation of olive oil nanoemulsion using sucrose monoester. Int. J. Pharm.
Pharm. Sci. 5, 434–440
163. Mustafa, M., Menon, J., Muiandy, R., Fredie, R. & Fariz, A. (2015). Risk factors,
diagnosis, and management of peptic ulcer disease. J. Dent. Med. Sci. 14, 40–46
164. Chen, H. et al. (2015). Protective effects of pogostone from Pogostemonis Herba
against ethanol-induced gastric ulcer in rats. Fitoterapia 100, 110–117
165. Milosavljevic T., Kostić-Milosavljević, M., Jovanović, I. & Krstić, M. (2011).
Complications of peptic ulcer disease. Dig. Dis. 29, 491–493
166. Bertleff, M. J. O. E. & Lange, J. F. (2010). Laparoscopic correction of perforated
peptic ulcer: first choice? A review of literature. Surg. Endosc. 24, 1231–1239
167. Forssell, H. (1988). Gastric mucosal defence mechanisms: a brief review. Scand. J.
Gastroenterol. 23, 23–28
168. Cheng, Y., Macera, A. . C., Davis, R. D. & Blair, N. S. (2000). Physical activity
and peptic ulcers. West. J. Med. 173, 101–107
169. Boligona, A. A. et al. (2014). Antiulcerogenic activityof Scutia buxifolia on gastric
ulcers induced by ethanol in rats. Acta Pharm. B 4, 358–367
170. Kim, H. U. (2015). Diagnostic and treatment approaches for refractory peptic
ulcers. Clin. Endosc. 48, 285–290
171. Lundell, L., Vieth, M., Gibson, F., Nagy, P. & Kahrilas, P. J. (2015). Systematic
review: the effects of long‐term proton pump inhibitor use on serum gastrin levels
and gastric histology. Aliment. Pharmacol. Ther. 42, 649–663
172. Park, J. U. et al. (2019). Gastroprotective effects of plants extracts on gastric
mucosal injury in experimental sprague-dawley rats. Biomed Res. Int. 2019, 1–11
173. Jidong Sun. (2007). D-limonene : safety and clinical applications. Altern. Med.
Rev. 12, 259–264
121
174. Rozza, A. L. et al. (2011). Gastroprotective mechanisms of Citrus lemon
(Rutaceae) essential oil and its majority compounds limonene and -pinene:
Involvement of heat-shock protein-70, vasoactive intestinal peptide, glutathione,
sulfhydryl compounds, nitric oxide and prostaglandin E2. Chem. Biol. Interact.
189, 82–89
175. De Souza, M. C. et al. (2018). Gastroprotective effect of limonene in rats:
influence on oxidative stress, inflammation and gene expression. Phytomedicine
53, 37–42
176. Miller, J. A. et al. (2014). Human breast tissue disposition and bioactivity of
limonene in women with early stage breast cancer. Cancer Prev. Res. 6, 577–584
177. Jaroenkit, P., Nisoa, M. & Matan, N. (2011). In vitro and in vivo activity of
citronella oil for the control of spoilage bacteria of semi dried round scad
(Decapterus maruadsi). Int. J. Med. Aromat. Plants 1, 234–239
178. Mehannaa, M. M., Domiati, S., Chmaisse, H. N. & El Mallah, A. (2018).
Antinociceptive effect of tadalafil in various pain models: involvement of opioid
receptors and nitric oxide cyclic GMP pathway. Toxicol. Appl. Pharmacol. 352,
170–175
179. Mostafa, T. (2016). Non-sexual implications of phosphodiesterase type 5
inhibitors. Sex. Med. Rev. 5, 1–30
180. Duffin, R., Shaw, C. A. & Rossi, A. G. (2008). Sildenafil reduces alcohol-induced
gastric damage:just say ‘NO’. Br. J. Pharmacol. 153, 623–624
181. Karakaya, K. et al. (2009). Mitigation of indomethacin-induced gastric mucosal
lesions by a potent specific type V phosphodiesterase inhibitor. World J.
Gastroenterol. 15, 5091–5096
182. Sawatzky, D. A., Megson, I. L. & Rossi, A. G. (2005). Sildenafil offers protection
against NSAID-induced gastric injury. Br. J. Pharmacol. 146, 477–478
183. Kolawole, A. & Francis, S. O. (2012). Effects of a type V phosphodiesterase
inhibitor (tadalafil) on indomethacin-induced gastric ulceration in rats. Int. J. Trop.
Med. 7, 111–117
184. Cheong, A. M. et al. (2018). Improvement of gastroprotective and anti-ulcer effect
of kenaf seed oil-in-water nanoemulsions in rats. Food Sci. Biotechnol. 27, 1175–
1184
185. Abdelwahab, S. et al. (2015). Thymoquinone-loaded nanostructured lipid carriers:
preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after
122
extravascular administration. Int. J. Nanomedicine 2163–2172
186. Nasr, A., Gardouh, A. R., Ghonaim, H. M. & Ghorab, M. M. (2016). Design,
formulation and in-vitro characterization of Irbesartan solid self-nanoemulsifying
drug delivery system (S-SNEDDS) prepared using spray drying technique. J.
Chem. Pharm. Res. 8, 159–183
187. Saranya, S., Chandrasekaran, N. & Mukherjee, A. (2012). Antibacterial activity of
eucalyptus oil nanoemulsion against Proteus Mirabilis. Int. J. Pharm. Pharm. Sci.
4, 668–671
188. Jeevana, J. & K, S. (2011). Design and evaluation of self-nanoemulsifying drug
delivery system of flutamide. J. Young Pharm. 3, 4–8
189. Chrastina, A. et al. (2018). Plumbagin-loaded nanoemulsion drug delivery
formulation and evaluation of antiproliferative effect on prostate cancer cells.
Biomed Res. Int. 2018, 1–7
190. Khan, K. & Rhodes, C. (1972). Effect of compaction pressure on the dissolution
efficiency of some direct compression systems. Pharm. Acta Helv. 47, 594–607
191. Al-hamidi, H., Edwards, A. A., Mohammad, M. A. & Nokhodchi, A. (2010). To
enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride
as a potential carrier in solid dispersion formulations. Colloids Surfaces B
Biointerfaces 76, 170–178
192. Mehanna, M. M., Motawaa, A. M. & Samaha, M. W. (2010). In sight into tadalafil
– block copolymer binary solid dispersion: mechanistic investigation of dissolution
enhancement. Int. J. Pharm. 402, 78–88
193. Abou Zeit-har, M., Verimer, T. & Long, J. P. (1982). . Pharmazie 593–595
194. Sabiu, S., Garuba, T., Taofik Olatunde Sunmonu, A. O. S. & Ismail, N. O. (2016).
Indomethacin-induced gastric ulceration in rats: ameliorative roles of spondias
mombin and ficus exasperata. Pharm. Biol. 54, 180–186
195. Mehanna, M. M., Alwattar, J. K. & Elmaradny, H. A. (2015). Optimization,
physicochemical characterization and in vivo assessment of spray dried emulsion: a
step toward bioavailability augmentation and gastric toxicity minimization. Int. J.
Pharm. 496, 766–779
196. Moleiro, F. C. et al. (2009). Mouriri elliptica : validation of gastroprotective ,
healing and anti- Helicobacter pylori effects. J. Ethnopharmacol. 123, 359–368
197. Mehanna, M. M., Motawaa, A. M. & Samaha, M. W. (2011). Tadalafil inclusion in
microporous silica as effective dissolution enhancer: optimization of loading
123
procedure and molecular state characterization. J. Pharm. Sci. 100, 1805–1818
198. Shakeel, F. & Faisal, M. S. (2010). Nanoemulsion: A promising tool for solubility
and dissolution enhancement of celecoxib. Pharm. Dev. Technol. 15, 53–56
199. Nasr, A., Gardouh, A. & Mamdouh, G. (2016). Novel solid self-nanoemulsifying
drug delivery system (s-snedds) for oral delivery of olmesartan medoxomil: design,
formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics 8, 1–
29
200. Moon-Jeong, R. & Clarence A., M. (1999). Spontaneous emulsification of oils
containing hydrocarbon, nonionic surfactant, and oleyl alcohol. J. Colloid Interface
Sci. 209, 179–192
201. Subramanian, P. & Siddalingam, R. (2017). Self-nanoemulsifying drug delivery
systems of poorly soluble drug dutasteride: formulation and in-vitro
characterization. J. Appl. Pharm. Sci. 7, 11–22
202. Bali, V., Ali, J. & Ali, M. (2011). Nanocarrier for the enhanced bioavailability of a
cardiovascular agent: In vitro,pharmacodynamic, pharmacokinetic and stability
assessment. Int. J. Pharm. 403, 46–56
203. Dash, R., Mohammed, H., Touseef, H. & Devi, R. (2015). Design, optimization
and evaluation of glipizide solid self-nanoemulsifying drug delivery for enhanced
solubility and dissolution. Saudi Pharm. J. 23,
204. Avachat, A. M. & Patel, V. G. (2015). Self nanoemulsifying drug delivery system
of stabilized ellagic acid – phospholipid complex with improved dissolution and
permeability. Saudi Pharm. J. 23, 276–289
205. Ali, H. H. & Hussein, A. A. (2017). Oral nanoemulsions of candesartan cilexetil:
formulation, characterization and in vitro drug release studies. Am. Assoc. Pharm.
Sci. 3, 1–16
206. Yi, Z. et al. (2010). Self-nanoemulsifying drug delivery system (SNEDDS) for oral
delivery of Zedoary essential oil: formulation and bioavailability studies. Int. J.
Pharm. Pharm. 383, 170–177
207. El-Badry, M., Haq, N., Fetih, G. & Shakeel, F. (2014). Solubility and dissolution
enhancement of tadalafil using self-nanoemulsifying drug delivery system. J. Oleo
Sci. 63, 567–576
208. Varshosaz, J., Taymouri, S., Hamishehkar, H., Razieh, V. & Yaghubi, S. (2017).
Development of dry powder inhaler containing tadalafil-loaded PLGA
nanoparticles. Res. Pharm. Sci. 12, 222–232
124
209. Dorota, W., Krzak, J., Macikowski, B. & Berkowski, R. (2019). Evaluation of the
release kinetics of a pharmacologically active substance from model intra-articular
implants replacing the cruciate ligaments of the knee. MDPI:Materials 12, 1–13
210. Alvarez-Suarez, J. M. et al. (2011). Strawberry polyphenols attenuate ethanol-
induced gastric lesions in rats by activation of antioxidant enzymes and attenuation
of MDA increase. PLoS One 6, 1–11
211. Chandranath, S., Bastaki, S. & Singh, J. (2002). A comparative study on the
activity of lansoprazole, omeprazole and pd‐136450 on acidified ethanol‐ and
indomethacin‐induced gastric lesions in the rat. Clin. Exp. Pharmacol. Physiol. 29,
173–180
212. Guzmán-Gómez, O. et al. (2018). Amelioration of ethanol induced gastric ulcers in
rats pretreated with Phycobiliproteins of Arthrospira (Spirulina) Maxima. Nutrients
10, 1–15
213. Shin, J. M. & Kim, N. (2013). Pharmacokinetics and pharmacodynamics of the
proton pump inhibitors. J. Neurogastroenterol. Motil. 19, 25–35
214. Yandrapu, H. & Sarosiek, J. (2016). Protective factors of the gastric and duodenal
mucosa an overview protective factors of the gastric and duodenal mucosa : an
overview. Curr. Gastroenterol. Rep. 17, 1–8
215. Thabrew, M. & Arawwawala, L. (2016). An overview of in vivo and in vitro
models that can be used for evaluating anti-gastric ulcer potential of medicinal
plants. Austin Biol. 1, 1–9
216. Oliveira, F. de A., Andrade, L. N., De Sousa, É. B. V. & De Sousa, D. P. (2014).
Anti-ulcer activity of essential oil constituents. Molecules 19, 5717–5747
217. Hibbitts, A. & O’Leary, C. (2018). Emerging nanomedicine therapies to counter
the rise of methicillin-resistant staphylococcus aureus. MDPI:Materials 11, 321
218. Weiner, L. et al. (2016). Antimicrobial-resistant pathogens associated with
healthcare-associated infections: summary of data reported to the national
healthcare safety network at the centers for disease control and prevention, 2011–
2014. Infect. Control Hosp. Epidemiol. 174, 1–14
219. Dakheel, K. H. et al. (2016). Methicillin-resistant staphylococcus aureus biofilms
and their influence on bacterial adhesion and cohesion. Biomed Res. Int. 2016, 1–
14
220. Rather, I. A., Kim, B., Bajpai, V. K. & Park, Y. (2017). Self-medication and
antibiotic resistance : crisis , current challenges , and prevention. Saudi J. Biol. Sci.
125
24, 808–812
221. Bjarnsholt, T. (2013). The role of bacterial biofilms in chronic infections. APMIS J.
Pathol. Microbiol. Immunol. 121, 1–58
222. Arciola, C. R., Campoccia, D., Speziale, P., Montanaro, L. & Costerton, J. W.
(2012). Biofilm formation in Staphylococcus implant infections. a review of
molecular mechanisms and implications for biofilm-resistant materials.
Biomaterials 33, 5967–5982
223. Golan, Y. (2019). Current treatment options for acute skin and skin- structure
infections. Clin. Infect. Dis. 68, 206–212
224. Bispo, P. J. M., Haas, W. & Gilmore, M. S. (2015). Biofilms in infections of the
eye. Pathogens 4, 111–136
225. Saraswathi, P. & Beuerman, W. R. (2015). Corneal biofilms: from planktonic to
microcolony formation in an experimental keratitis infection with Pseudomonas
Aeruginosa. Ocul. Surf. 13, 331–345
226. Chang, V. S. et al. (2016). Antibiotic resistance in the treatment of Staphylococcus
aureus keratitis: a 20-year review. Cornea. 34, 698–703
227. Erik, T. & Webster, T. J. (2011). Reducing infections through nanotechnology and
nanoparticles. Int. J. Nanomedicine 6, 1463–1473
228. Ahmed, K., Swetha, S., Aravind, S., Ganapathy, V. & Anbazhagan, V. (2014).
Preparation of Gold nanoparticles using Salicornia Brachiata plant extract and
evaluation of catalytic and antibaterial activity. Spectrochim. Acta, Part A Mol.
Biomol. Spectrosc. 130, 54–58
229. Priyanka, R. & Bhattacharyya, S. (2018). A review on promising antibiotic therapy
by novel delivery systems. Asian J. Pharm. Clin. Res. 11, 18–24
230. Linette, S. et al. (2012). Liposomal encapsulation of vancomycin improves killing
of methicillin-resistant Staphylococcus aureus in a murine infection model. J.
Antimicrob. Chemother. 67, 2191–2194
231. Muppidi, K., Jeffrey, W., Betageri, G. & Pumerantz, A. S. (2011). PEGylated
liposome encapsulation increases the lung tissue concentration of vancomycin.
Antimicrob. Agents Chemother. 55, 4537–4542
232. Kalhapure, R. S. et al. (2015). Solid lipid nanoparticles of clotrimazole silver
complex : an efficient nano antibacterial against Staphylococcus aureus and
MRSA. Colloids Surfaces B Biointerfaces 136, 651–658
233. Khan, M., Ali, M. & Ali, M. (2019). Curcumin-loaded self-emulsifying drug
126
delivery system ( cu-SEDDS ): a promising approach for the control of primary
pathogen and secondary bacterial infections in cutaneous leishmaniasis. Appl.
Microbiol. Biotechnol. 1–10
234. Phumat, P., Khongkhunthian, S., Rades, T., Müllertz, A. & Okonogi, S. (2019).
Development of 4-Allylpyrocatechol loaded self-nanoemulsifying drug delivery
system for enhancing water solubility and antibacterial activity against oral
pathogenic bacteria. Int. J. Pharmacol. Pharm. Sci. 13, 2019
235. Akram, A., Majed, S. & Miaad, S. (2018). The antidiabetic and antioxidant
properties of some phenolic phytochemicals: A review study. Diabetes Metab.
Syndr. Clin. Res. Rev. 13, 854–857
236. Naveet, P. & Archana, B. (2018). Resveratrol: from enhanced biosynthesis and
bioavailability to multitargeting chronic diseases. Biomed. Pharmacother. 109,
2237–2251
237. Sun, Y., Zheng.G-J, Feng.B & Zhang.Y.Q. (2018). Phytochemicals: current
strategy to sensitize cancer cells to cisplatin. Biomed. Pharmacother. 110, 518–527
238. Cui.H, Li.C, Lin.L & Zhang.C. (2018). Antimicrobial mechanism of clove oil on
listeria monocytogenes. Food Control 94, 140–146
239. Panatieri, L. F. et al. (2016). Nanoemulsions containing a coumarin-rich extract
from Pterocaulon balansae ( Asteraceae ) for the treatment of ocular Acanthamoeba
keratitis. AAPS PharmSciTech 18, 721–728
240. Vuuren, S. F. Van & Viljoen, A. M. (2007). Antimicrobial activity of limonene
enantiomers and 1 , 8-cineole alone and in combination. Flavour Fragr. J. 22, 540–
544
241. Khan, A. W., Ansari, S. H., Sharma, R. K., Ali, J. & Kotta, S. (2015). Self-
nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble
grapefruit flavonoid Naringenin: design, characterization, in vitro and in vivo
evaluation. Drug Deliv. 22, 552–561
242. Weinstein, M. P. (2018). Methods for Dilution Antimicrobial Susceptibility Tests
for Bacteria That Grow Aerobically. The Clinical & Laboratory Standards Institute
(CLSI) 112
243. Tre-Hardy, M., Traore, H., Devleeschouwer, M. J. & Vanderbist, F. (2008). In
vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm
and planktonic cultures. Int. J. Antimicrob. Agents 31, 329–336
244. Abdelaziz, A. A., Sonbol, F. l, Gamaleldin, N. M., Maghraby, G. M. EL &
127
Elbanna, T. E. (2014). Optimization of niosomes for enhanced antibacterial activity
and reduced bacterial resistance: in vitro and in vivo evaluation. Expert Opin. Drug
Deliv. 12, 163–180
245. Liu, R. et al. (2016). Thermosensitive in situ nanogel as ophthalmic delivery
system of curcumin: development, characterization, in vitro permeation and in vivo
pharmacokinetic studies. Pharm. Dev. Technol. 21, 576–582
246. Ammar, H. O., Salama, H. A., Ghorab, M. & Mahmoud, A. A. (2010).
Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular
delivery. Drug Dev. Ind. Pharm. 36, 1330–1339
247. Patel, N. et al. (2016). Development of loteprednol etabonate-loaded cationic
nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular
bioavailability. Drug Deliv. 23, 3712–3723
248. Miyazaki, S. et al. (2001). In situ gelling xyloglucan formulations for sustained
release ocular delivery of pilocarpine hydrochloride. Int. J. Pharm. 229, 29–36
249. Varshosaz, J., Tabbakhian, M. & Salmani, Z. (2008). Designing of a
thermosensitive chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin.
Open Drug Deliv. J. 2, 61–70
250. Luepke, N. P. & Kemper, F. H. (1986). The HET-CAM Test: an alternative to the
draize eye test. Food Chem. Toxicol. 24, 495–496
251. Freire, P. L. et al. (2015). Action of silver nanoparticles towards biological
systems: Cytotoxicity evaluation using hen’s egg test and inhibition of
Streptococcus mutans biofilm formation. Int. J. Antimicrob. agents 45, 183–187
252. Mahmoud, D., Shukr, M. H. & Bendas, E. R. (2014). In vitro and in vivo
evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and
parenteral administration. Int. J. Pharm. 476, 60–69
253. Rajapandiyan, K. et al. (2018). Antimicrobial activity of nanoemulsion on drug-
resistant bacterial pathogens. Microb. Pathog. 120, 85–96
254. Vatsraj, S., Chauhan, K. & Pathak, H. (2014). Formulation of a novel
nanoemulsion system for enhanced solubility of a sparingly water soluble
antibiotic, clarithromycin. J. Nanosci. 2014, 1–9
255. Ranjini, D., Parthiban, S., Kumar, G. S. & Tamizh, M. (2017). Development of
levofloxacin loaded nano-niosomes as nanoscale drug delivery for effective
treatment of tuberculosis. World J. Pharm. Pharm. Sci. 6, 1819–1828
256. Debnath, U., Satayanarayana & Kumar, G. V. (2010). Nanoemulsion-a method to
128
improve the solubility of lipophilic drugs. An Int. J. Adv. Pharm. Sci. 2, 71–83
257. Galindo-Alvarez, J. et al. (2011). Enhanced stability of nanoemulsions using
mixtures of non-ionic surfactant and amphiphilic polyelectrolyte. Colloids Surfaces
A Physicochem. Eng. Asp. 389, 237–245
258. Shakeel, F., Haq, N., Alanazi, F. K. & Alsarra, I. A. (2014). Polymeric solid self-
nanoemulsifying drug delivery system of glibenclamide using coffee husk as a low
cost biosorbent. Powder Technol. 256, 352–360
259. Abouhussein, D. M. N., Bahaa, D. & Din, E. (2019). Design of a liquid nano-sized
drug delivery system with enhanced solubility of rivaroxaban for venous
thromboembolism management in paediatric patients and emergency cases. J.
Liposome Res. 1–14
260. Choi, K.-O., Aditya, N. & Ko, S. (2014). Effect of aqueous pH and electrolyte
concentration on structure, stability and flow behavior of non-ionic surfactant
based solid lipid nanoparticles. Food Chem. 147, 239–244
261. Kassem, A. A., Mohsen, A. M., Ahmed, R. S. & Essam, T. M. (2016). Self-
nanoemulsifying drug delivery system ( SNEDDS ) with enhanced solubilization of
nystatin for treatment of oral candidiasis : Design , optimization , in vitro and in
vivo evaluation. J. Mol. Liq. 218, 219–232
262. Jerobin, J. et al. (2015). Antibacterial activity of neem nanoemulsion and its
toxicity assessment on human lymphocytes in vitro. Int. J. Nanomedicine 10, 77–
86
263. Li, Z.-H., Cai, M., Liu, Y.-S., Sun, P.-L. & Luo, S.-L. (2019). Antibacterial activity
and mechanisms of essential oil from citrus medica l.var.sarcodactylis. Molecules
24, 1–10
264. Moghimi, R., Ghaderi, L., Rafati, H., Aliahmadi, A. & McClements, D. J. (2016).
Superior antibacterial activity of nanoemulsion of Thymus daenensis essential oil
against E.coli. Food Chem. 194, 410–415
265. Song, Z. et al. (2016). Enhanced efficacy and anti-biofilm activity of novel
nanoemulsions against skin burn wound multi-drug resistant MRSA infections.
Nanomedicine Nanotechnology, Biol. Med. 12, 1543–1555
266. Ramalingam, K. & Lee, V. A. (2018). Antibiofilm activity of an EDTA-containing
nanoemulsion on multidrug-resistant Acinetobacter baumannii. Artif. Cells,
Nanomedicine, Biotechnol. 46, S737–S743
267. Gadad, A. P., Wadklar, P. D., Dandghi, P. & Patil, A. (2016). Thermosensitive In
129
situ gel for ocular delivery of Lomefloxacin. Pharm. Res. 50, S96-105
268. Yumei, W. et al. (2019). Research progress of in-situ gelling ophthalmic drug
delivery system. Asian J. Pharm. Sci. 14, 1–15
269. Yumei, W. et al. (2019). Research progress of in-situ gelling ophthalmic. Asian J.
Pharm. Sci. 14, 1–15
270. Makwana, S. B., Patel, V. A. & Parmar, S. J. (2016). Development and
characterization of in-situ gel for ophthalmic formulation containing cipro fl oxacin
hydrochloride. Results Pharma Sci. 6, 1–6
271. Srividya, B., Cardoza, R. M. & Amin, P. D. (2001). Sustained ophthalmic delivery
of ofloxacin from a pH triggered in situ gelling system. J. Control. Release 73,
205–211
272. Morsi, N., Ghorab, D., Refai, H. & Teba, H. (2016). Ketoroloac tromethamine
loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged
ocular delivery. Int. J. Pharm. 506, 57–67
273. Laddha, U. D. & Mahajan, H. S. (2017). An insight to ocular in situ gelling
systems. Int. J. Adv. Pharm. 06, 31–40
274. Derakhshandeh, K., Fashi, M. & Seifoleslami, S. (2010). Thermosensitive
Pluronic® hydrogel: prolonged injectable formulation for drug abuse. Drug Des.
Devel. Ther. 4, 255–262
275. Sina, J. F. & Gautheron, P. D. (1994). A Multitest Approach to Evaluating Ocular
Irritation in Vitro. Toxicol. methods 4, 41–49
276. Chaiyana, W. et al. (2017). Inhibition of 5α-reductase, il-6 secretion, and oxidation
process of equisetum debile roxb. Ex vaucher extract as functional food and
nutraceuticals ingredients. Nutrients 9, 1–17